Back to discover

Protein / target

Tumor necrosis factor receptor superfamily member 9

Encoded byTNFRSF9Q07011Homo sapiensSwiss-Prot
Clinical-stage
Therapeutic maturity
2
Clinical candidates
9
Clinical trials
Small-molecule tractable
Druggability
Structure with Ligand

Protein at a glance

Biological role

Signaling receptor

Strongest disease association

Immunodeficiency 109 with lymphoproliferation

Via encoding gene TNFRSF9 · Genetic literature evidence · score 0.61

Therapeutic position

Clinically advancing target

Antibodies

Research activity

Emerging research

2 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Receptor for TNFSF9/4-1BBL.

View complete UniProt function annotation

Receptor for TNFSF9/4-1BBL. Conveys a signal that enhances CD8(+) T-cell survival, cytotoxicity, and mitochondrial activity, thereby promoting immunity against viruses and tumors (Probable)

Subcellular location

Cell membrane
Domains and Gene Ontology detail (6)

Gene Ontology

  • Cexternal side of plasma membrane
  • Cplasma membrane
  • Fsignaling receptor activity
  • Papoptotic process
  • Pnegative regulation of cell population proliferation
  • Pregulation of cell population proliferation

255 aa · 28 kDa

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell proliferation & survivalUniProt · GO
View supporting evidence

Cell proliferation & survival

  • ·Receptor for TNFSF9/4-1BBL. Conveys a signal that enhances CD8(+) T-cell survival, cytot…
  • ·negative regulation of cell population proliferation
  • ·regulation of cell population proliferation
View underlying pathways (1)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

TNFSF9TNFSF4CD247CD70TRAF1CD80LGALS9CD28LOC102…ICOSLGTNFRSF9

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

urelumab
Narrow target profilePhase 2Agonist

Tumor necrosis factor receptor superfamily member 9 agonist

Direct interaction with this protein · Only this protein recorded as a target

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene TNFRSF9

Gene-level evidence surfaced through the gene TNFRSF9that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Immunodeficiency 109 with lymphoproliferation
0.64Moderately supported

Genetic evidence dominant · Open Targets 0.52

Hair color
0.40Limited support

Genetic evidence dominant · Open Targets 0.24

Chronic venous hypertension
0.39Limited support

Genetic evidence dominant · Open Targets 0.24

Genetic Diseases, Inborn
0.31Limited support

Genetic evidence dominant · Open Targets 0.19

Osteoarthritis, Knee
0.25Preliminary

Genetic evidence dominant · Open Targets 0.15

View evidence synthesis (5)
Immunodeficiency 109 with lymphoproliferationModerately supported
0.64
agreement 0.510.76
Genetic83%Animal model17%Genetic literaturedup

Open Targets aggregate 0.52 · 2 independent evidence families · 1 not counted as duplicate

Hair colorLimited support
0.40
agreement 0.280.52
Genetic100%

Open Targets aggregate 0.24 · 1 independent evidence family

Chronic venous hypertensionLimited support
0.39
agreement 0.270.51
Genetic100%

Open Targets aggregate 0.24 · 1 independent evidence family

Genetic Diseases, InbornLimited support
0.31
agreement 0.170.45
Genetic99%Literature1%

Open Targets aggregate 0.19 · 2 independent evidence families

Osteoarthritis, KneePreliminary
0.25
agreement 0.130.37
Genetic100%

Open Targets aggregate 0.15 · 1 independent evidence family

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Immunodeficiency 109 with lymphoproliferation0.52
Hair color0.24
Chronic venous hypertension0.24
Genetic Diseases, Inborn0.19
Osteoarthritis, Knee0.15
Total joint arthroplasty0.15
Osteoarthritis, Hip0.15
Lymphoma, Large B-Cell, Diffuse0.14
Breast Neoplasms0.12
Melanoma0.12

Drug development

2 compounds recorded · 2 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 1 drug that targets this protein in Forefront's canonical graph: these count different sets and are not a subset relation.

View all recorded compounds (2)
URELUMABPhase 2
UTOMILUMABPhase 3

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesEmerging

Feasibility evidence (structure with ligand) — no clinical-stage drug of this modality recorded.

AntibodiesStrong

Advanced Clinical and GO CC high conf support this modality.

Protein degradersEmerging

Feasibility evidence (database ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (7)
SM · Structure with LigandAB · Advanced ClinicalAB · GO CC high confAB · UniProt loc med confAB · UniProt SigP or TMHMMAB · Human Protein Atlas locPR · Database Ubiquitination

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

9

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

ClinicalTrials.gov via the drug-target graph.

What's happening now

1

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. New publication2016-10-18
    Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.

    Clinical cancer research : an official journal of the American Association for Cancer Research · 2017 · 313 citations · Europe PMC · via urelumab

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.

Research activity

2 papers · to 2024

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Europe PMC papers linked directly to this protein.